All very good questions. I actually tried to reach out to Pfizer as well but couldn't get my email to get through for some reason. I need to call them to mention what others have observed here as well. They may already know of peoples inflamation relief etc. I also would suspect people have noted this with their primary care physicians as well which may help the cause if they hear this on an ongoing basis? Remember physicians see their pharmacuetical reps. on a routine basis, which you would think might be passed along this way as well.
As I mentioned previously, many companies become aware of not only the negative side effects but the positive as well which may prompt them to seek approval to begin additional trials for the new indication, in this case arthritic relief, which to me is huge. I'm fairly sure the drug in it's present form is obviously only recommended/prescribed for short term usage, 5 days, with respect to covid. It's definitely possibe it could be reformulated for long term usage but of course trials would need to take place with respect to efficacy for the control of inflamation etc. and safety, typically with respect to cardiac effects. The safety part of it would probably be easily achieveable since it's already met that threshold, at least in todays format/dosage. Unfortunately trials for efficacy would most likely take longer to see how it works in blind studies vs. placebos etc. Trials typically take a few years at best but hard to say here as it's already met some FDA hurdles. I sure wish it was simpler as it sure seems to have improved peoples daily functions, at least for a short period of time. I am going to see if I can find out if Pfizer is indeed looking at this possibility. BTW, I am actually a shareholder as well so I may go through investor relations and see if I can learn anything. I wish all well and Merry Christmas to all.